Search
Aytu Biopharma Inc
AYTUAdd to Watchlist
2.160USD
+0.010+0.47%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
23.18MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.47%
5 Days
-4.00%
1 Month
-5.68%
6 Months
-16.92%
Year to Date
-16.92%
1 Year
-0.92%
Key Figures
2.130Open
2.190High
7.28KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.07%Turnover Ratio
2.150Prev. Close
2.120Low
12.77KTurnover
LossP/E Static
1.63P/B
0.00%Div Yield TTM
-28.93%ROA
3.06552wk High
0.32Volume Ratio
-13.56MNet Profit
10.73MShares
-4.6080EPS TTM
0.25Beta
-97.42%ROE
1.46052wk Low
3.26%Amplitude
55.10%Gross Margin
23.18MMarket Cap
0.71Reward/Risk
3.37%Risk Rate
TradingKey Stock Score of Aytu Biopharma Inc
Currency: USD Updated: 2026-06-30Key Insights
Aytu Biopharma Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 85 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.50.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Aytu Biopharma Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Aytu Biopharma Inc Highlights
StrengthsRisks
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.
Growing
The company is in a growing phase, with the latest annual income totaling USD 66.38M.
Overvalued
The company’s latest PE is -0.47, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.87M shares, decreasing 11.30% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
9.500
Target Price
+341.86%
Upside Space
Aytu Biopharma Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Aytu Biopharma Inc Info
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.
Ticker SymbolAYTU
CompanyAytu Biopharma Inc
CEODisbrow (Joshua R)
Websitehttps://aytubio.com/
Related Instruments
-0.64%
-0.05%
-2.95%
-0.23%
-2.41%
-1.64%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
FAQs
What is the current price of Aytu Biopharma Inc (AYTU)?
The current price of Aytu Biopharma Inc (AYTU) is 2.15.
What is the symbol of Aytu Biopharma Inc?
The ticker symbol of Aytu Biopharma Inc is AYTU.
What is the 52-week high of Aytu Biopharma Inc?
The 52-week high of Aytu Biopharma Inc is 3.06.
What is the 52-week low of Aytu Biopharma Inc?
The 52-week low of Aytu Biopharma Inc is 1.46.
What is the market capitalization of Aytu Biopharma Inc?
The market capitalization of Aytu Biopharma Inc is 23.08M.
Is Aytu Biopharma Inc (AYTU) currently rated as Buy, Hold, or Sell?
According to analysts, Aytu Biopharma Inc (AYTU) has an overall rating of Buy, with a price target of 9.50.
What is the Earnings Per Share (EPS TTM) of Aytu Biopharma Inc (AYTU)?
The Earnings Per Share (EPS TTM) of Aytu Biopharma Inc (AYTU) is -2.16.